Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Mark D Pegram1, Yu Zong1, Clinton Yam1
1From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.
Abstract:
Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicity compared with cytotoxic chemotherapies and often induce response or durable disease control in estrogen receptor (ER) and/or HER2+ breast cancers. Drugs that target CDK 4/6 either alone or in combination with endocrine therapy have demonstrated substantial improvements in progression-free survival (PFS) compared with endocrine monotherapy. Most recently, PARP inhibitors have shown longer PFS compared with physician's choice of chemotherapy in BRCA-associated cancers, leading to the first U.S. Food and Drug Administration (FDA) approval of a targeted therapy with the potential to benefit a subgroup of patients with triple-negative breast cancer (TNBC). Finally, newer drug delivery strategies using antibody drug conjugates have also allowed a "targeted approach" to deliver moderate to extremely potent cytotoxins directly to sites of metastatic disease, with less toxicity.
Insights
Targeted therapies, including CDK 4/6 inhibitors and PARP inhibitors, offer improved progression-free survival for metastatic breast cancer patients. Antibody drug conjugates provide a targeted approach to deliver potent cytotoxins with reduced toxicity.
Area of Science:
- Oncology
- Pharmacology
- Medical Science
Background:
- Metastatic breast cancer (MBC) is a significant global health challenge.
- Targeted therapies show promise in managing ER+ and HER2+ breast cancers, offering improved outcomes and reduced toxicity compared to traditional chemotherapy.
- Emerging treatments are expanding therapeutic options for MBC patients.
Purpose of the Study:
- To review recent advancements in targeted therapies for metastatic breast cancer.
- To highlight the efficacy of CDK 4/6 inhibitors, PARP inhibitors, and antibody drug conjugates in MBC treatment.
- To discuss the potential of these targeted approaches in improving patient survival and quality of life.
Main Methods:
- Review of clinical trial data and recent literature on targeted therapies for MBC.
- Analysis of progression-free survival (PFS) data for CDK 4/6 inhibitors and PARP inhibitors.
- Evaluation of antibody drug conjugate strategies for targeted drug delivery in metastatic disease.
Main Results:
- CDK 4/6 inhibitors combined with endocrine therapy significantly improve PFS in ER+ breast cancer.
- PARP inhibitors demonstrate longer PFS compared to chemotherapy in BRCA-associated cancers, leading to FDA approval for a subset of TNBC.
- Antibody drug conjugates enable targeted delivery of potent cytotoxins, potentially reducing systemic toxicity.
Conclusions:
- Targeted therapies represent a significant advancement in the management of metastatic breast cancer.
- CDK 4/6 inhibitors and PARP inhibitors offer improved PFS and are valuable additions to the MBC treatment landscape.
- Novel drug delivery systems like antibody drug conjugates enhance treatment efficacy and tolerability.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
01:26Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:52Persuasion Strategies
01:27Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...